Publications by authors named "Yunchun Long"

Claim this Profile
C
Cost-effectiveness analysis of Toripalimab regimen for extensive-stage small-cell lung cancer in China and America.
Jing Yang, Fang Chen, Junlin Li, Yujie Zhou, Hao Wang, Yunchun Long

Front Immunol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma.
Lei Xu, Yunchun Long, Lu Yao, Hao Wang, Weihong Ge

Front Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China.
Yunchun Long, Hao Wang, Xianhai Xie, Junlin Li, Yuan Xu

BMJ Open· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evaluation of serplulimab plus chemotherapy as the first-line treatment of oesophageal squamous cell carcinoma in China.
Fang Chen, Yunchun Long, Jiayong Yang, Kailong Zhong, Bili Liu

BMJ Open· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China.
Yunchun Long, Yuan Xu, Li Liao, Yujie Zhou, Hao Wang

BMJ Open· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer.
Hao Wang, Yunchun Long, Yuan Xu, Li Liao, Yujie Zhou

Front Public Health· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China.
Hao Wang, Li Liao, Yuan Xu, Yunchun Long, Ye Wang

Front Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis